These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 30642575)

  • 1. Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.
    Drusbosky LM; Vidva R; Gera S; Lakshminarayana AV; Shyamasundar VP; Agrawal AK; Talawdekar A; Abbasi T; Vali S; Tognon CE; Kurtz SE; Tyner JW; McWeeney SK; Druker BJ; Cogle CR
    Leuk Res; 2019 Feb; 77():42-50. PubMed ID: 30642575
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting AMPK-ULK1-mediated autophagy for combating BET inhibitor resistance in acute myeloid leukemia stem cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Autophagy; 2017 Apr; 13(4):761-762. PubMed ID: 28118076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AMPK-ULK1-Mediated Autophagy Confers Resistance to BET Inhibitor JQ1 in Acute Myeloid Leukemia Stem Cells.
    Jang JE; Eom JI; Jeung HK; Cheong JW; Lee JY; Kim JS; Min YH
    Clin Cancer Res; 2017 Jun; 23(11):2781-2794. PubMed ID: 27864418
    [No Abstract]   [Full Text] [Related]  

  • 4. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
    Drusbosky LM; Singh NK; Hawkins KE; Salan C; Turcotte M; Wise EA; Meacham A; Vijay V; Anderson GG; Kim CC; Radhakrishnan S; Ullal Y; Talawdekar A; Sikora H; Nair P; Khanna-Gupta A; Abbasi T; Vali S; Guha S; Farhadfar N; Murthy HS; Horn BN; Leather HL; Castillo P; Tucker C; Cline C; Pettiford L; Lamba JK; Moreb JS; Brown RA; Norkin M; Hiemenz JW; Hsu JW; Slayton WB; Wingard JR; Cogle CR
    Blood Adv; 2019 Jun; 3(12):1837-1847. PubMed ID: 31208955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
    Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
    Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
    Braun T; Gardin C
    Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose triptolide enhances antitumor effect of JQ1 on acute myeloid leukemia through inhibiting RNA polymerase II in vitro and in vivo.
    Shi Y; Zhao H; Ye J; Li Z; Deng M; Zha J; Zhou Y; Zeng H; Lin Y; Pu X; Guo C; Song H; Qiu Y; Xu B
    Mol Carcinog; 2020 Sep; 59(9):1076-1087. PubMed ID: 32691884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML.
    Gerlach D; Tontsch-Grunt U; Baum A; Popow J; Scharn D; Hofmann MH; Engelhardt H; Kaya O; Beck J; Schweifer N; Gerstberger T; Zuber J; Savarese F; Kraut N
    Oncogene; 2018 May; 37(20):2687-2701. PubMed ID: 29491412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET Bromodomain inhibition promotes De-repression of TXNIP and activation of ASK1-MAPK pathway in acute myeloid leukemia.
    Zhou Y; Zhou J; Lu X; Tan TZ; Chng WJ
    BMC Cancer; 2018 Jul; 18(1):731. PubMed ID: 29996811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of distinctive long noncoding RNA competitive interactions and a six-methylated-gene prognostic signature in acute myeloid leukemia with -5/del(5q) or -7/del(7q).
    Yin X; Huang S; Xu A; Fan F; Chen L; Sun C; Hu Y
    J Cell Biochem; 2020 Feb; 121(2):1563-1574. PubMed ID: 31535409
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment.
    Pérez-Peña J; Serrano-Heras G; Montero JC; Corrales-Sánchez V; Pandiella A; Ocaña A
    Mol Cancer Ther; 2016 Aug; 15(8):1823-33. PubMed ID: 27256375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).
    Welti J; Sharp A; Yuan W; Dolling D; Nava Rodrigues D; Figueiredo I; Gil V; Neeb A; Clarke M; Seed G; Crespo M; Sumanasuriya S; Ning J; Knight E; Francis JC; Hughes A; Halsey WS; Paschalis A; Mani RS; Raj GV; Plymate SR; Carreira S; Boysen G; Chinnaiyan AM; Swain A; de Bono JS;
    Clin Cancer Res; 2018 Jul; 24(13):3149-3162. PubMed ID: 29555663
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical Trials.
    Albrecht BK; Gehling VS; Hewitt MC; Vaswani RG; Côté A; Leblanc Y; Nasveschuk CG; Bellon S; Bergeron L; Campbell R; Cantone N; Cooper MR; Cummings RT; Jayaram H; Joshi S; Mertz JA; Neiss A; Normant E; O'Meara M; Pardo E; Poy F; Sandy P; Supko J; Sims RJ; Harmange JC; Taylor AM; Audia JE
    J Med Chem; 2016 Feb; 59(4):1330-9. PubMed ID: 26815195
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRD4: a BET(ter) target for the treatment of AML?
    Valent P; Zuber J
    Cell Cycle; 2014; 13(5):689-90. PubMed ID: 24526121
    [No Abstract]   [Full Text] [Related]  

  • 15. Computational modeling of early T-cell precursor acute lymphoblastic leukemia (ETP-ALL) to identify personalized therapy using genomics.
    Kumar A; Drusbosky LM; Meacham A; Turcotte M; Bhargav P; Vasista S; Usmani S; Pampana A; Basu K; Tyagi A; Lala D; Rajagopalan S; Birajdar SC; Alam A; Ghosh Roy K; Abbasi T; Vali S; Sengar M; Chinnaswamy G; Shah BD; Cogle CR
    Leuk Res; 2019 Mar; 78():3-11. PubMed ID: 30641417
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DNA hypermethylation: Computational modeling of DNA demethylation treatment of acute myeloid leukemia.
    Przybilla J; Hopp L; Lübbert M; Loeffler M; Galle J
    Epigenetics; 2017; 12(10):886-896. PubMed ID: 28758855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia.
    Nahi H; Lehmann S; Bengtzen S; Jansson M; Möllgård L; Paul C; Merup M
    Leuk Lymphoma; 2008 Mar; 49(3):508-16. PubMed ID: 18297528
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.
    Albert DH; Goodwin NC; Davies AM; Rowe J; Feuer G; Boyiadzis M; Dorritie KA; Mancini M; Gandour-Edwards R; Jonas BA; Borthakur G; Aldoss I; Rizzieri DA; Odenike O; Prebet T; Singh S; Popovic R; Shen YU; McDaniel KF; Kati WM; Modi DA; Motwani M; Wolff JE; Frost DJ
    In Vivo; 2022; 36(4):1615-1627. PubMed ID: 35738590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the multi-kinase inhibitor midostaurin in combination with chemotherapy in models of acute myeloid leukaemia.
    Weisberg E; Meng C; Case AE; Tiv HL; Gokhale PC; Buhrlage SJ; Yang J; Liu X; Wang J; Gray N; Adamia S; Sattler M; Stone R; Griffin JD
    J Cell Mol Med; 2020 Mar; 24(5):2968-2980. PubMed ID: 31967735
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
    Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
    Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.